A5033843290- Economic and Financial Impacts of Cancer
- Health Systems, Economic Evaluations, Quality of Life
- Gastric Cancer Management and Outcomes
- Epigenetics and DNA Methylation
- Neutropenia and Cancer Infections
- Multiple and Secondary Primary Cancers
- Pancreatic and Hepatic Oncology Research
- Pharmacy and Medical Practices
- Palliative Care and End-of-Life Issues
- Pharmacological Effects and Toxicity Studies
- Medical Research and Treatments
- Lung Cancer Treatments and Mutations
- Renal cell carcinoma treatment
- Chemotherapy-induced organ toxicity mitigation
- Clinical practice guidelines implementation
- Bladder and Urothelial Cancer Treatments
- Statistical Methods in Clinical Trials
- Dialysis and Renal Disease Management
Cancer Institute of New South Wales
2012-2024
Abstract Aim To understand the current usage of eviQ Cancer Treatments Online ( www.eviQ.org.au ), an Australian, open‐access website providing evidence‐based and consensus‐driven cancer treatment protocols information, extent to which it is meeting its intended outcomes value users. Methods A mixed‐method evaluation was conducted in 2020−2022 included a review key program documentation data, delivery focused online survey Results In 2022, 329 clinicians representing all Australian states...
e17507 Background: eviQ is an Australian, web-based point-of-care information resource which aims to improve cancer outcomes by supporting evidence-based practice. Over the last decade, has provided access more than 500 treatment protocols in Medical/Radiation Oncology, Haematology and Cancer Genetics. Each chemotherapy protocol a schedule, administering instructions, side effects, key evidence patient information. Protocols are developed consultation with oncology, haematology genetics...
e13518 Background: Anticancer drug dosing recommendations in kidney dysfunction are often empirical, based on non-standardised creatinine assays calculated via the Cockcroft-Gault equation, and lack applicability to globally accepted classifications. ADDIKD aims provide a standardised approach assessing function cancer patients, apply evidence consensus-based anticancer dysfunction. Methods: An expert international multidisciplinary working group was established develop recommendations. The...
Abstract Background Evidence supporting dose modifications to reduce serious treatment‐related adverse events of antineoplastic therapy is limited and frequently based on clinical trial protocols, which are not always generalisable community patients. eviQ an online resource with treatment protocols recommendations for modification formulated by expert opinion evidence‐based review. Original recommended haematological thresholds delay were: neutrophil count <1.5 × 10 9 /L platelet <100...